MENU
+Compare
JAGX
Stock ticker: NASDAQ
AS OF
Jun 27 closing price
Price
$2.50
Change
-$0.21 (-7.75%)
Capitalization
3.31M

JAGX Jaguar Health Inc Forecast, Technical & Fundamental Analysis

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea... Show more

JAGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for JAGX with price predictions
Jun 27, 2025

JAGX in -14.38% downward trend, declining for three consecutive days on June 27, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where JAGX declined for three days, in of 420 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Aroon Indicator for JAGX entered a downward trend on June 27, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Moving Average Convergence Divergence (MACD) for JAGX just turned positive on June 10, 2025. Looking at past instances where JAGX's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .

JAGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.858) is normal, around the industry mean (16.366). P/E Ratio (0.009) is within average values for comparable stocks, (58.189). JAGX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.309). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (0.092) is also within normal values, averaging (252.247).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. JAGX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JAGX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
JAGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of pharmaceuticals

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Generic
Address
200 Pine Street
Phone
+1 415 371-8300
Employees
49
Web
http://www.jaguar.health
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NCPL5.680.95
+20.08%
NETCAPITAL INC.
EWBC101.112.28
+2.31%
East West Bancorp
HLMN7.140.07
+0.99%
Hillman Solutions Corp
SWIM6.580.06
+0.92%
Latham Group
WIMI2.97-0.05
-1.82%
WiMi Hologram Cloud Inc

JAGX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, JAGX has been closely correlated with WINT. These tickers have moved in lockstep 90% of the time. This A.I.-generated data suggests there is a high statistical probability that if JAGX jumps, then WINT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JAGX
1D Price
Change %
JAGX100%
-7.75%
WINT - JAGX
90%
Closely correlated
+21.49%
CDTX - JAGX
90%
Closely correlated
+0.24%
NCNA - JAGX
89%
Closely correlated
N/A
SNPX - JAGX
89%
Closely correlated
+23.37%
RNAC - JAGX
89%
Closely correlated
-6.81%
More

Groups containing JAGX

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JAGX
1D Price
Change %
JAGX100%
-7.75%
JAGX
(21 stocks)
20%
Poorly correlated
+0.39%